Patents Examined by Cecilia J. Tsang
  • Patent number: 8691749
    Abstract: The present invention provides a peptide comprising an amino acid sequence of SEQ ID NO: 1 and a pharmaceutically acceptable salt thereof effective for treating degenerative disc diseases, treating body organ fibrosis, treating cancer and/or treating glomerulosclerosis, and effective for the inhibition of TGF-beta 1 signaling.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: April 8, 2014
    Assignee: Ensoltek Co., Ltd.
    Inventors: Hae Jin Kim, Eun Joung Moon, Yang Seon Kim, Young Joon Kwon
  • Patent number: 8691756
    Abstract: The present application describes a method of treating a bacterial infection comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a defined macrocycle compound.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: April 8, 2014
    Assignee: Novartis AG
    Inventors: Roger Aki Fujimoto, Philipp Krastel, Matthew J. LaMarche
  • Patent number: 8691528
    Abstract: According to the present invention, it is possible to provide a novel cell penetrating peptide that transports proteins into cells and/or into nuclei at higher frequency than conventional cell penetrating peptides, and a pharmaceutical containing the peptide.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: April 8, 2014
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Shusei Uno, Kaeko Kamide, Hiroshi Nakakubo
  • Patent number: 8691763
    Abstract: The present invention provides methods for treating, preventing and/or ameliorating at least one cardiovascular disorder in a human in need thereof comprising administering to said human a pharmaceutical composition comprising at least one polypeptide having at least one GLP-1 activity and/or at least one GLP-1 agonist.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: April 8, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Beat M. Jucker, John J. Lepore, Eric J. Olson
  • Patent number: 8685372
    Abstract: The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide or aptamer that specifically binds to the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that specifically bind to neurons or nerves and for compositions thereof.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: April 1, 2014
    Assignee: The Regents of the University of California
    Inventors: Roger Y. Tsien, Quyen T. Nguyen, Michael Whitney
  • Patent number: 8686026
    Abstract: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: April 1, 2014
    Assignee: AbbVie Inc.
    Inventors: Bernd Liepold, Tina Jung, Peter Hölig, Rudolf Schroeder, Nancy E. Sever, Justin S. Lafountaine, Brent D. Sinclair, Yi Gao, Jianwei Wu
  • Patent number: 8680054
    Abstract: The invention relates to novel topical pharmaceutical compositions in which the active agent is a cyclic depsipeptide of formula (II) and to methods for manufacturing such compositions.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: March 25, 2014
    Assignee: Novartis AG
    Inventor: Claire Haug
  • Patent number: 8680152
    Abstract: The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: March 25, 2014
    Assignee: Virobay, Inc.
    Inventor: Robert Booth
  • Patent number: 8680062
    Abstract: A novel class of oligomeric compounds designed for forming conjugates with biologically active substances and delivering these substances to a desired bodily target are disclosed. Novel conjugates of these oligomeric compounds and biologically active moieties, pharmaceutical compositions containing such conjugates, and uses thereof as delivery systems for delivering the biologically active substances to a desired target are further disclosed. Processes of preparing the conjugates and the oligomeric compounds and novel intermediates designed for and used in these processes are also disclosed.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: March 25, 2014
    Assignee: Deliversir Ltd.
    Inventor: David Segev
  • Patent number: 8680048
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: March 25, 2014
    Assignee: AbbVie Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
  • Patent number: 8680052
    Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: March 25, 2014
    Assignee: The Medicines Company
    Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats, David J. Schneider
  • Patent number: 8680240
    Abstract: ClotFoam is a sealant and hemostatic agent for use in cases of non-compressible hemorrhage for moderate to severe bleeding. It can be applied in the operating room through laparoscopic ports, or directly over lacerated tissue in laparotomy procedures or outside the operating room through a mixing needle and/or a spray injection method following intracavitary severe trauma or surgery. Its crosslinking technology generates an adhesive scaffold that carries a fibrin sealant required for hemostasis. Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The composition is biocompatible and non-inflammatory. The invention uses fibrin monomer polymerized by a change of pH as active sealing component. The viscoelastic properties of the foam as well as the rapid formation of a fibrin clot ensure that the sealant remains at the site of application without being washed away by blood.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: March 25, 2014
    Inventor: George David Falus
  • Patent number: 8673850
    Abstract: A method for identifying a compound for preventing or treating a LDLR-associated disease, a VLDLR-associated disease or an ApoER2-associated disease, said method comprising determining whether: a) a level of expression of Annexin A2 nucleic acid or encoded polypeptide; b) a level of Annexin A2 activity; or c) a combination of a) and b), is increased in the presence of a test compound relative to in the absence of said test compound, wherein said increase is indicative that said test compound can be used for preventing or treating a LDLR-associated disease, a VLDLR-associated disease, an ApoER2-associated disease.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: March 18, 2014
    Assignee: Institut de Recherches Cliniques de Montreal
    Inventors: Nabil G. Seidah, Gaétan Mayer, Steve Poirier
  • Patent number: 8673860
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: March 18, 2014
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wel Wang, Benjamin Spink, Willem P. Stemmer, Nathan C. Geething, Wayne To, Jeffrey L. Cleland
  • Patent number: 8673270
    Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radio imaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for in targeted chemotherapy.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: March 18, 2014
    Assignee: Steba Biotech S.A.
    Inventors: Doron Eren, Tamar Yechezkel, Yoseph Salitra, Natalia Koudinova
  • Patent number: 8674020
    Abstract: There is provided a novel process for preparing polyamides (in particular cyclic and hairpin polyamides) comprising the step of coupling an amine with a Boc-protected amino acid monomer in the presence of diphosgene and/or triphosgene. Such a process may be performed on a solid or solution phase.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: March 18, 2014
    Assignee: University of Leicester
    Inventors: Wu Su, Glenn Ashley Burley
  • Patent number: 8669229
    Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxo-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: March 11, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Kazumi Kondo, Yasuhiro Menjo, Takahiro Tomoyasu, Shin Miyamura, Yuso Tomohira, Takakuni Matsuda, Keigo Yamada, Yusuke Kato
  • Patent number: 8663617
    Abstract: The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: March 4, 2014
    Assignee: Tufts University
    Inventor: Ira M Herman
  • Patent number: 8658591
    Abstract: Disclosed herein are PACE4 inhibitors, compositions comprising PACE4 inhibitors and their uses thereof for lowering PACE4 activity, reducing cell proliferation, reducing tumor growth, reducing metastasis formation, preventing and/or treating cancer. Also provided are methods for lowering PACE4 activity, reducing the proliferation of a cell, reducing tumor growth and/or treating and preventing cancer. Methods for screening PACE4 inhibitors and cell proliferation inhibitors are further provided.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: February 25, 2014
    Inventors: Robert Day, Martin Fugère, Witold A. Neugebauer
  • Patent number: 8653235
    Abstract: Provided are a cyclic peptide compound or a pharmacologically acceptable salt thereof capable of inhibiting parakeratosis of skin, and a method for producing the same.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: February 18, 2014
    Assignee: Kwansei Gakuin Educational Foundation
    Inventors: Yohei Hirai, Yoji Okugawa